Results from a prognostic genomic assay convinced a group of Spanish oncologists to change treatment plans for 56% of 89 patients with HER2-positive (HER2+) early breast cancer.
A safety analysis following a randomized phase 3 trial confirms that vomiting and nausea are common in patients who take the drug trastuzumab deruxtecan to treat HER2-low metastatic breast cancer.
Kantarjian receives the highest honor from the American Society of Clinical Oncology (ASCO) for his lifelong contributions to leukemia research and patient care.
A combination of venetoclax, ibrutinib, and obinutuzumab outperforms first-line chemoimmunotherapy for chronic lymphocytic leukemia in otherwise fit adults with few comorbidities.